Biased signaling; potential agonist and antagonist of PAR2

Protease activated receptor 2 (PAR2) has emerged as one of the promising therapeutic targets to inhibit rapidly metastasizing breast cancer cells. However, its elusive molecular mechanism of activation and signaling has made it a difficult target for drug development. In this study, in silico methods were used to unfold PAR2 molecular mechanism of signaling based on the concept of GPCR receptor plasticity. Although, there are no conclusive evidences of the presence of specific endogenous ligands for PAR2, the efficacy of synthetic agonist and antagonist in PAR2 signaling has opened up the possibilities of ligand mediated signaling. Furthermore, it has been proved that ligands specific for one GPCR can induce signaling in receptors belonging to other subfamilies. Therefore, the aim of the present study was to identify potential agonists and antagonists from the GPCR ligand database (GLL), which may induce biased signaling in PAR2 using the concept of existence of multiple ligand stabilized receptor conformations. The results of our in silico study suggest that PAR2 may show biased signaling with agonists of serotonin type1, β adrenergic type 1 and antagonists of substance K (NK1), serotonin type 2, dopamine type 4 and thromboxane receptors. Further, this study could also throw light on the putative ligand specific conformations of PAR2. Thus, the results of this study provide structural insights to putative conformations of PAR2 and also gives initial clues to medicinal chemists for rational drug design targeting this challenging receptor.